Arrhythmias & electrophysiologyRandomised controlled trial
Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention
- Randomised controlled trial
- prospective
- parallel-group
- 1:1 randomisation
- enrollment terminated prematurely (COVID-19)
- Enrollment terminated prematurely due to the COVID-19 pandemic; planned sample size not reached
Authors' conclusion
In this trial, there was no evidence that screening for AF using a 14-day continuous electrocardiographic monitor in people ≥70 years of age seen in primary care practice reduces stroke hospitalizations.
Study context
- Population
- People aged ≥70 years in primary care practices, 149 US sitesITT population
- Participants
- 11,905 people
- Comparison
- Atrial fibrillation (AF) screening with 14-day continuous ECG patch monitor vs usual care
- Primary endpoint
- Hospitalization due to all-cause stroke
- Follow-up
- Median 15.3 months
Primary result
Stroke hospitalization
Hazard ratio
1.10
95% CI 0.69–1.75
By group
Screening vs Usual care
HR 1.10 (95% CI 0.69–1.75)
As reported in the abstract
Further findings
AF diagnosis
OAC initiation after randomisation
Safety
| Outcome | Screening | Usual care | HR (95% CI) | |
|---|---|---|---|---|
| Bleeding (primary safety outcome) | 1.0% | 1.1% | 0.87 (0.60–1.26) | |
| 0.512Hazard ratio (log scale) |
Original publication
Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention. J Am Coll Cardiol. Published 1 September 2024. doi:10.1016/j.jacc.2024.08.019
Summarised from the published abstract; every number is checked against it